Reference Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

Ref Type
Authors Guopan Yu, Weiguo Zhang, Charlie Ly, Hongying Zhang, William Rice and Michael Andreeff
Title CG '806, a Novel Pan-FLT3/BTK Multi-Kinase Inhibitor, Induces Cell Cycle Arrest, Apoptosis or Autophagy in AML Cells Depending on FLT3 Mutation Status
Abstract Text Blood 2017 130:4629


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
CG-806 CG'806|CG-026806|CG806|Luxeptinib BTK inhibitor 36 FLT3 Inhibitor 66 CG-806 is a small molecule multi-kinase inhibitor that inhibits both wild-type and mutant Flt3 and Btk, resulting in growth inhibition in tumor cells (Blood 2017 130:4629).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
FLT3 wild-type acute myeloid leukemia predicted - sensitive CG-806 Preclinical - Cell culture Actionable In a preclinical study, CG-806 inhibited Btk and aurora kinase activation, induced G2/M arrest and autophagy in acute myeloid leukemia cells harboring wild-type FLT3 in culture (Blood 2017 130:4629). detail...